ProQR Therapeutics (PRQR) Current Deferred Revenue (2014 - 2026)

ProQR Therapeutics has reported Current Deferred Revenue for 12 years, with the latest figure at $23.0 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 13.36% year-over-year to $23.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.0 million (up 13.36% YoY) and the FY2025 annual result came in at $20.4 million, down 12.86% from the prior year.
• Current Deferred Revenue advanced to $23.0 million in Q1 2026 per PRQR's latest filing, from $20.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $69.6 million in Q1 2023 and troughed at $5.8 million in Q4 2022.
• A 5-year average of $26.9 million and a median of $22.1 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue jumped 2211913.24% in 2022, then slumped 67.88% in 2024.
• Over 5 years, Current Deferred Revenue stood at $5.8 million in 2022, then jumped by 284.54% to $22.1 million in 2023, then grew by 5.95% to $23.4 million in 2024, then declined by 12.86% to $20.4 million in 2025, then advanced by 12.35% to $23.0 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $23.0 million, $20.4 million, and $20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.